Tyrosine kinase inhibitors

• US 9,688,676 B2
• Filed: 01/19/2017
• Issued: 06/27/2017
• Est. Priority Date: 06/03/2015
• Status: Active Grant

• Current Assignee: Principia Biopharma Inc. (Sanofi )
• Original Assignee: Principia Biopharma Inc. (Sanofi )
• Inventors: Owens, Timothy D.
• Primary Examiner(s): Rao, Deepak
• Assistant Examiner(s): DANIEL, LAURA M
• Application Number:
  US15/410,716
• Publication Number:
  US 20170129890A1
• Time in Patent Office: 159 Days
• Field of Search: None
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine

Abstract

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Claims

1. The compound

(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one

and/or

a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound and/or a pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable excipient.

3. A method of inhibiting BTK in a mammal in need thereof, wherein the method comprises administering to the mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of the compound and/or a pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable excipient.